Format

Send to

Choose Destination
Ann Oncol. 2018 Oct 1;29(10):2151. doi: 10.1093/annonc/mdx803.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

PMID:
29701763
DOI:
10.1093/annonc/mdx803

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center